Addenbrookes Hospital of Cambridge University Hospital NHS Foundation Trust (“CUHFT”)
Project Name: Addenbrookes Nurse Led Myeloproliferative Neoplasm (“MPN”) Service Development Project. Project period:12 months Joint working project summary: The aim of the Joint Working Project (“JWP”), between Novartis and the NHS team, will be to generate a new Addenbrookes Hospital Clinical Nurse Specialist (“CNS”) led MPN clinic service. The rationale is to generate a new innovative model of care which identifies MPN patients that may need a treatment review, improves patient satisfaction and clinical outcomes, along with increasing MPN clinic capacity and activity to generate a new service which is financially sustainable.
The JWP duration will be 12 months (9 months of clinic operations), at which point the results will be recorded in a JWP summary report. The NHS team will use the JWP summary report, the new CNS led MPN clinics operations and patient outcome results to present a case to the CUHFT board for the long term funding of the service after the JWP has completed. Expected patient outcomes from this project
A new CNS led MPN clinic service at Addenbrookes Hospital to identify patients that may be in need of a treatment review to improve the proportion optimally treated, improve patient satisfaction and clinical outcomes using the following assessments:
• Introduce a patient satisfaction questionnaire for MPN patients to complete upon entering the new CNS led MPN clinic service (to establish baseline) and repeat at 9 months. • Increase MPN patient satisfaction by 20% by the end of month 9 of the clinic service using a Trust validated patient satisfaction questionnaire. • All Chronic Myeloid Leukaemia (“CML”) patients to have their Molecular Responses (“MR”) measured and recorded using the Novartis Treatment Evaluation Toolkit upon entering the new CNS led MPN clinic (to establish baseline) and repeated at 3, 6 and 9 months of the new clinic service. • Increase the proportion of CML patients considered to be achieving optimum MR’s, by 20%, relative to sub-optimal and treatment failure in line with the European Leukaemia Network (“ELN”) 2013 recommendations by the end month 9 of Clinic Operations. • All Myelofibrosis (“MF”) patients to be receiving MPN10 symptom score assessments upon entering the new CNS led MPN clinic and repeated at months 3, 6 and 9 of the new clinic service. • All CML patients to receive an assessment upon entry in to the new CNS led MPN clinic, using the Novartis Cardiovascular Risk Assessment Toolkit and repeated at month 9 of Clinic Operations.
Start Date & Duration: June 2016 – June 2017 TAS15-C047c April 2016